Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature

Leuk Res. 2009 Jul;33(7):e69-72. doi: 10.1016/j.leukres.2009.01.008. Epub 2009 Feb 23.

Authors

Klaus H Metzeler, Stefan Boeck, Birgit Christ, Andreas Hausmann, Hans-Joachim Stemmler, Klaus G Parhofer, Helmut Ostermann, Wolfgang Hiddemann, Jan Braess

PMID: 19230970
DOI: 10.1016/j.leukres.2009.01.008

No abstract available

Publication types

Case Reports
Letter
Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Trials, Phase II as Topic
Cytarabine / administration & dosage
Female
Humans
Hyperammonemia / chemically induced*
Hyperammonemia / diagnosis
Hyperammonemia / therapy
Leukemia, Myeloid, Acute / drug therapy*
Middle Aged
Mitoxantrone / administration & dosage
Mutation
Nuclear Proteins / genetics
Nucleophosmin
fms-Like Tyrosine Kinase 3 / genetics

Substances

Nuclear Proteins
Cytarabine
Nucleophosmin
Mitoxantrone
FLT3 protein, human
fms-Like Tyrosine Kinase 3